Skip to main content
. 2021 Mar 24;9(3):e001458. doi: 10.1136/jitc-2020-001458

Figure 2.

Figure 2

Exploratory analysis of EPIC DNA methylation data of tumors from anti-programmed cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI)-treated patients with sarcoma. (A) Unsupervised hierarchical clustering of 35 patients with sarcoma based on beta values of 704,003 probes. The pink cluster is significantly enriched for responders (dark blue dots) to anti-PD-1 ICI, while the blue cluster contains only one responder to anti-PD-1 ICI. P values were calculated using Fisher’s exact tests; ns, not significant. (B) The volcano plot (middle panel) illustrates differentially methylated CpG sites (DMPs; green, hypomethylated; red, hypermethylated) between non-responders and responders to anti-PD-1 ICI. Each dot represents a unique DMP. The location of these DMPs relative to CpG islands and genomic features are shown in the upper and lower pie charts, respectively.